EC Paediatrics

Kaposi's varicelliform eruption (KVE) is a rare but serious complication that can occur in patients with atopic dermatitis (AD) affected by the herpes simplex virus (HSV). It is characterized by the rapid dissemination of HSV in AD-affected skin, resulting in widespread vesicular lesions mimicking the presentation of chickenpox. This condition can be triggered by various causes, such as bacterial or viral infections, or the use of immunosuppressants. KVE presents with an acute clinical course and can cause severe systemic complications, such as herpetic encephalitis, making early diagnosis and appropriate treatment crucial. Management includes systemic antiviral therapy, treatment of underlying dermatitis, and supportive measures. Although KVE is uncommon, its potential to cause significant morbidity underscores the importance of clinical surveillance in patients with AD and the need for appropriate therapy to prevent serious complications. A greater understanding of predisposing factors and underlying mechanisms is required to improve prevention and management of this unique clinical entity. At same time is presented one case of KVE with severe affection of the skin.

 Keywords: Kaposi's Varicelliform Eruption (KVE); Atopic Dermatitis (AD); Herpes Simplex Virus (HSV)

1. Kaposi M. “Pathologie und Therapie der Hautkrankheiten für prak tische Ärzte und Studirende”. 3^rd Wien: Urban & Schwarzenberg (1887).
2. Juliusberg F. “Über Pustulosis acuta varioliformis”. f. Derm. u. Syph. 46 (1898): 21-28.
3. Wollenberg A. “Eczema herpeticum”. Chemical Immunology and Allergy 96 (2012): 89-95.
4. Buxbaum S., et al. “Epidemiology of herpes simplex virus types 1 and 2 in Germany: what has changed?” Medical Microbiology and Immunology 3 (2003): 177-181.
5. Beck LA., et al. “Phenotype of atopic dermatitis subjects with a history of eczema herpeticum”. Journal of Allergy and Clinical Immunology 2 (2009): 260-9, 269.e1-7.
6. Wollenberg A., et al. “Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases”. Journal of the American Academy of Dermatology 2 (2003): 198-205.
7. Traidl S., et al. “Eczema herpeticum in atopic dermatitis”. Allergy 10 (2021): 3017-3027.
8. Bussmann C., et al. “Molecular pathogenesis and clinical implications of eczema herpeticum”. Expert Reviews in Molecular Medicine 10 (2008): e21.
9. Baringer JR and Swoveland P. “Recovery of herpes-simplex virus from human trigeminal ganglions”. New England Journal of Medicine 13 (1973): 648-650.
10. Bustos DE and Atherton SS. “Detection of herpes simplex virus type 1 in human ciliary ganglia”. Investigative Ophthalmology and Visual Science 7 (2002): 2244-2249.
11. Warren KG., et al. “Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings”. New England Journal of Medicine 19 (1978): 1068-1069.
12. Rahn E., et al. “Entry pathways of herpes simplex virus type 1 into human keratinocytes are dynamin- and cholesterol-dependent”. PLoS One10 (2011): e25464.
13. Suazo PA., et al. “Evasion of early antiviral responses by herpes simplex viruses”. Mediators of Inflammation (2015): 593757.
14. Spear PG and Longnecker R. “Herpesvirus entry: an update”. Journal of Virology 19 (2003): 10179-10185.
15. Thier K., et al. “Entry of herpes simplex virus 1 into epidermis and dermal fibroblasts is independent of the scavenger receptor MARCO”. Journal of Virology 15 (2018): e00490-18.
16. Petermann P., et al. “Role of nectin-1 and herpesvirus entry mediator as cellular receptors for herpes simplex virus 1 on primary murine dermal fibroblasts”. Journal of Virology 18 (2015): 9407-9416.
17. Nicoll MP., et al. “The molecular basis of herpes simplex virus latency”. FEMS Microbiology Reviews 3 (2012): 684-705.
18. Su C., et al. “Evasion of host antiviral innate immunity by HSV-1, an update”. Virology Journal 13 (2016): 38.
19. Damour A., et al. “Eczema herpeticum: clinical and pathophysiological aspects”. Clinical Reviews in Allergy and Immunology 1 (2020): 1-18.
20. Higgins CR., et al. “Natural history, management and complications of herpes labialis”. Journal of Medical Virology 1 (1993): 22-26.
21. Swart RN., et al. “Treatment of eczema herpeticum with acyclovir”. Archives of Dermatology 1 (1983): 13-16.
22. Yeh TC., et al. “Kaposi's varicelliform eruption in herpes simplex encephalitis”. Internal and Emergency Medicine6 (2016): 885-887.
23. Seegräber M., et al. “Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients”. Journal of the European Academy of Dermatology and Venereology 5 (2020): 1074-1079.
24. Wheeler CE Jr and Abele DC. “Eczema herpeticum, primary and recurrent”. Archives of Dermatology2 (1966): 162-173.
25. Wollenberg A., et al. “Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases”. Journal of the American Academy of Dermatology 2 (2003): 198-205.
26. Wutzler P., et al. “Klinische und virologische Untersuchungen zum Ekzema herpeticatum [Clinical and virological studies of eczema herpeticum]”. Dermatologische Monatschrift4 (1985): 222-229.
27. LeGoff J., et al. “Diagnosis of genital herpes simplex virus infection in the clinical laboratory”. Virology Journal 11 (2014): 83.
28. Traidl S., et al. “Eczema herpeticum in atopic dermatitis”. Allergy10 (2021): 3017-3027.
29. Mathes EF., et al. “"Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak”. Pediatrics1 (2013): e149-e157.
30. Wheeler CE Jr and Abele DC. “Eczema herpeticum, primary and recurrent”. Archives of Dermatology2 (1966): 162-173.
31. Khan A., et al. “Fifteen-minute consultation: eczema herpeticum in a child”. Archives of Disease in Childhood: Education and Practice Edition2 (2015): 64-68.
32. Piret J and Boivin G. “Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management”. Antimicrobial Agents and Chemotherapy 2 (2011): 459-472.
33. Wollenberg A. “Eczema herpeticum”. Chemical Immunology and Allergy 96 (2012): 89-95.
34. Frisch S and Siegfried EC. “The clinical spectrum and therapeutic challenge of eczema herpeticum”. Pediatric Dermatology1 (2011): 46-52.
35. Darji K., et al. “Characterization of children with recurrent eczema herpeticum and response to treatment with interferon-gamma”. Pediatric Dermatology6 (2017): 686-689.
36. Morata Alba J and Morata Alba L. “Erupción variceliforme de Kaposi. A propósito de un caso”. Revista de Pediatría de Atención Primaria [online] 74 (2017): 157-161.
37. Wang V., et al. “The infectious complications of atopic dermatitis”. Annals of Allergy, Asthma and Immunology1 (2021): 3-12.
38. Napolitano M., et al. “Children atopic dermatitis: Diagnosis, mimics, overlaps, and therapeutic implication”. Dermatologic Therapy12 (2022): e15901.
39. Luca NJ., et al. “Eczema herpeticum in children: clinical features and factors predictive of hospitalization”. Journal of Pediatrics 4 (2012): 671-675.